BROAD SPECTRUM MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR BOTULISM

Xoma Corporation, Berkeley CA

Investigators

Abstract

This contract supports the advanced development of promising biodefense therapeutic candidates/products with broad spectrum activity. The research and development activities supported will allow candidate therapeutic countermeasures to progress through the product development pipeline, and includes preclinical/non-clinical and clinical IND development activities.